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To investigate the heart rate during cardio-pulmonary exercise (CPX) testing in individuals
with type 1 diabetes (T1D) compared to healthy (CON) individuals. Fourteen people
(seven individuals with T1D and seven CON individuals) performed a CPX test until
volitional exhaustion to determine the first and second lactate turn points (LTP1 and LTP2),
ventilatory thresholds (VT1 and VT2), and the heart rate turn point. For these thresholds
cardio-respiratory variables and percentages of maximum heart rate, heart rate reserve,
maximum oxygen uptake and oxygen uptake reserve, and maximum power output were
compared between groups. Additionally, the degree and direction of the deflection of the
heart rate to performance curve (kHR) were compared between groups. Individuals with
T1D had similar heart rate at LTP1 (mean difference)−11, [(95% confidence interval)−27
to 4 b.min−1], at VT1 (−12, −8 to 33 b.min
−1) and at LTP2 (−7, −13 to 26 b.min
−1), at
VT2 (−7, −13 to 28 b.min
−1), and at the heart rate turn point (−5, −14 to 24 b.min−1)
(p = 0.22). Heart rate expressed as percentage of maximum heart rate at LTP1, VT1,
LTP2, VT2 and the heart rate turn point as well as expressed as percentages of heart
rate reserve at LTP2, VT2 and the heart rate turn point was lower in individuals with T1D
(p < 0.05). kHR was lower in T1D compared to CON individuals (0.11 ± 0.25 vs. 0.51 ±
0.32, p= 0.02). Our findings demonstrate that there are clear differences in the heart rate
response during CPX testing in individuals with T1D compared to CON individuals. We
suggest using submaximal markers to prescribe exercise intensity in people with T1D,
as the heart rate at thresholds is influenced by kHR.
Clinical Trial Identifier: NCT02075567 (https://clinicaltrials.gov/ct2/show/
NCT02075567).
Keywords: exercise prescription, heart rate to performance curve, thresholds, type 1 diabetes, heart rate reserve
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INTRODUCTION
Low amounts of structured exercise such as 3 × 30min per
week are associated with consistent improvements in health
status in already healthy and physically active individuals (1). In
people with both type 1 (T1D) and type 2 diabetes high doses
of physical activity were found to be associated with a 40% and
29% lower risk of all-cause mortality and cardiovascular disease
in comparison with inactivity (2).
Currently, standard exercise recommendations for individuals
with T1D are similar to those for healthy individuals, namely
150min or more of moderate to intense exercise and physical
activity spread over at least three days per week, or a minimum
of 75min per week of vigorous-intensity exercise/physical
activity (3, 4).
Intriguingly, the American Diabetes Association (ADA)
recommends prescribing exercise intensity as percentages of
maximum heart rate (5) even though there is an ongoing debate
on how to prescribe exercise intensity (6, 7). It was shown
that the variable time course of the heart rate to performance
curve influences exercise prescription, translating to uncertainty
to overestimate target training loads especially in the vigorous-
intensity domain (8–11). Using percentages of maximum heart
rate might be problematic as degree and direction of the
deflection of the heart rate to performance curve (kHR) during
CPX testing are altered in some healthy individuals (12) and
might be further impaired by autonomic cardiac neuropathy in
T1D individuals (13).
Furthermore, in T1D individuals with autonomic cardiac
neuropathy, left ventricular function was found to be decreased
in both systole and diastole, non-dipping was more prevalent,
and pulse pressure was higher compared to patients without
autonomic cardiac neuropathy (14). The heart rate to
performance curve was shown to be related to myocardial
function (15, 16). An increase in heart rate during CPX testing
reflects the ability of the autonomic nervous system to respond
to an increase in metabolic demands. In healthy individuals the
increase in heart rate during CPX testing is mainly originated
by a withdrawal of tonic vagal activity (17). As shown recently,
individuals with T1D reveal a higher risk of impaired tonic vagal
activity in comparison to their healthy counterparts (18). This
impaired response of the autonomic nervous system might alter
heart rate to performance curve, as found in our cohort.
Abbreviations: T1D, Type 1 diabetes/individuals with Type 1 diabetes; HbA1c,
Glycated hemoglobin; BMI, Body mass index; ADA, American Diabetes
Association; %HRmax, Percentages of maximum heart rate; HR, Heart rate; kHR,
Degree and direction of the deflection of the heart rate to performance curve;
CPX, Cardio-pulmonary exercise testing; CON, Healthy individuals; %HRR,
Percentages of heart rate reserve; %VO2max, Percentages of maximum oxygen
uptake; %VO2R, Percentages of oxygen uptake reserve; %Pmax, Percentages of
maximum power output; GCP, Good clinical practice; DoH, Declaration of
Helsinki; MDII, Multiple daily insulin injections; CRF, Case Report Form; Pmax,
Maximum power output; LTP1, First lactate turn point; LTP2, Second lactate turn
point; VT1, First ventilatory threshold; VT2, Second ventilatory threshold; VE,
Ventilation; VE/VO2, Ventilation of oxygen; VE/VCO2, Ventilation of carbon
dioxide; HRTP, Heart rate turn point; MD, Mean difference; CI, confidence
interval.
As shown previously, different threshold concepts are suitable
for healthy (6, 19) and T1D individuals (20, 21). The first
threshold occurring during cardio-pulmonary exercise (CPX)
testing [e.g., first lactate turn point (LTP1) or the first ventilatory
threshold (VT1)] translates to the inability of the muscle to
entirely oxidize produced lactate and therefore it is partly shifted
into the blood stream and can be metabolized by other organs.
At this first threshold there is still a metabolically balanced
condition but on a systemic level (22). At the second threshold
[e.g., second lactate turn point (LTP2) or the second ventilatory
threshold (VT2)] produced lactate in the workingmuscles cannot
be muscularly or systemically eliminated, resulting in a blood
lactate accumulation (metabolically unbalanced condition, no
lactate steady state) (6).
The aim of the study was to investigate the time course of
the heart rate to performance curve during CPX testing in T1D
individuals compared to matched healthy individuals (CON),
and to prove its influence on percentages of maximum heart rate,
percentages heart rate reserve, percentages maximum oxygen
uptake, percentages oxygen uptake reserve and percentages
maximum power output compared to standard markers of
submaximal performance between groups. We determined as a
primary outcome the heart rate to performance curve during
CPX testing and its impact on target training heart rate
determination in comparison of T1D individuals and matched
healthy individuals (CON) and as secondary outcomes the
functional capacity, cardiorespiratory and metabolic markers in
comparison of groups during CPX testing. We hypothesized that
people with T1D show an altered heart rate to performance curve
during CPX testing and this impacts target training heart rate
determination.
METHODS
Consent Procedures
This study was carried out in accordance with the
recommendations of Good Clinical Practice (GCP), “Bundesamt
fuer Sicherheit im Gesundheitswesen” (BASG Austria). The
protocol was approved by the ethics committee of the Medical
University of Graz, AT (26-069 ex 13/14). All subjects gave
written informed consent in accordance with the Declaration
of Helsinki. CON individuals were matched from routine
diagnostics (approved by the Ministry of Science).
Eligibility Criteria and Assessment
To be eligible for the study, T1D individuals had to be male,
diagnosed with T1D for at least 12 months, aged between 18
and 35 years (both inclusive), glycated hemoglobin (HbA1c) ≤
8% (64 mmol.mol−1), fasting c-peptide negative, treated with
multiple daily insulin injections, no long-term complications and
no other physical and/or mental diseases, which might influence
the study results. In this primary investigation we recruited
male individuals as the female menstrual cycle may influence
the energy supply during CPX testing (23). Participants were
excluded if they had a history of any disease that might confound
the results of the trial, use of drugs, which may interfere with
the interpretation of the trial’s results or known to be clinically
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relevant in interfering with insulin action, glucose utilization
or recovery from hypoglycemia, current addiction to alcohol
or any controlled substance abuse. Furthermore, participants
were excluded if they had known or suspected allergy to trial
products or related products, mental incapacity, unwillingness,
language barriers precluding adequate understanding, and any
condition that the study physician feels would interfere with
the trial participation. Testing day exclusion criteria were:
hypoglycemia 48 h prior to testing, illness on or before the
testing day, low glucose levels immediately before testing (≤ 4.4
mmol.l−1) or alcohol consumption 24 h before. All data were
assessed and documented in a standardized Case Report Form.
CON individuals were selected with respect to T1D individuals’
characteristics (matched for sex, age, and maximum power
output) from routine diagnostics data at the entry to the physical
education studies. CON individuals were instructed to avoid
intense or long-lasting exercise 24 h prior to the investigation
and to avoid alcohol within 24 h pre-testing. Written informed
consent was obtained from all participants.
Participants Characteristics
T1D individuals’ characteristics were: age 24 ± 5 years (min–
max; 19–32), BMI 23.9 ± 2.5 kg.m−2 (20–28), HbA1c 7.4 ±
0.6% (6.5–8) (57 ± 6.3 mmol.mol−1) (47–64), c-peptide 0.13 ±
0.19 nmol.l−1 (0–0.4) and total daily insulin dose with insulin
Degludec 41 ± 16U (27–69). Four participants used bolus
insulin Aspart (Novo Rapid, Novo Nordisk, Denmark) and three
participants used bolus insulin Lispro (Humalog/ Lilly, USA).
Before switching to insulin Degludec, two patients used insulin
Detemir (Levemir/ Novo Nordisk, Denmark) and five patients
used insulin Glargine (Lantus/ Sanofi- Aventis, France) as basal
therapy. T1D participants were free of comorbidities and co-
medications other than insulin. CON individuals were aged 23
± 4 years (19–30), had a BMI of 23.4 ± 1.8 kg.m2 (21–26) and
were healthy without taking any medications.
Study Procedures
In this experimental design, T1D individuals were adjusted
to the same therapy with insulin Degludec ( R©Tresiba/Novo
Nordisk, Dagsvaerd, Denmark) as part of a basal-bolus routine.
After a run-in period of 4 weeks with insulin Degludec, a
CPX test was performed. Insulin Degludec was used to achieve
homogeneity for the basal insulin therapy. We have chosen
insulin Degludec since its pharmacodynamic profile is flat and
stable, demonstrated by an even distribution of glucose-lowering
effects across the 24-h period (24).
Cardio-Pulmonary Exercise (CPX) Testing
Fourteen participants performed a maximum CPX test on a
cycle ergometer (Monark Ergomedic 839E, Monark, Sweden) at
the Sports Science Institute, University of Graz, Austria (25).
Participants were permitted to cycle at a cadence of 70–90
rpm. At the beginning of the CPX testing, participants sat on
the cycle ergometer for 3min without pedaling (0W). Then,
participants started to cycle for 3min with a workload of 40W.
Subsequently, the workload was increased by 20W every minute
until volitional exhaustion, followed by 3min of active recovery
at 40W and 3min of passive recovery (0W). LTP1 and LTP2
(12) as well as VT1 and VT2 were determined from the CPX
test by means of a computer-based linear regression break point
analysis (6). LTP1 was defined as the first increase in capillary
blood lactate concentration above baseline values and LTP2 was
defined as the second abrupt increase between LTP1 and the
maximum power output. VT1 was defined as the first increase in
ventilation (VE) accompanied by an increase in VE/VO2 without
an increase in VE/VCO2. VT2 was defined as the second abrupt
increase in VE accompanied by an increase in both VE/VO2 and
VE/VCO2. Additionally, the heart rate turn point was defined as
the point of intersection of two regression lines in the heart rate
to performance curve between LTP1 and the maximum power
output with minimal standard deviation of the two straight lines.
The degree and direction of the deflection of the heart rate
to performance curve (kHR) was calculated by a second-degree
polynomial function between LTP1 and the maximum power
output (12, 21).
MEASUREMENTS
Pulmonary gas-exchange variables were measured continuously
during CPX testing via breath-by-breath measurement and 5 s
average (ZAN 600, ZAN, Germany). Heart rate was measured
continuously via chest belt telemetry and 5 s average (PE 4000,
Polar Electro, Finland). A 12-lead electrocardiogram and blood
pressure measurements (every 2min) were obtained during CPX
testing for cardiac monitoring. Blood lactate and blood glucose
(for safety in T1D group) concentrations were determined by
taking capillary blood samples from the earlobe at the end of
the rest and warm-up periods, at the end of each workload
step (every minute), and at the end of active and passive
recovery. Blood lactate and blood glucose were analyzed by
means of an enzymatic-amperometric method ( R©Biosen S-line,
EKF Diagnostics, Germany).
Bolus Insulin Dose Reduction
After overnight fasting, T1D individuals received a standardized
meal on the day of the CPX test ( R©Fortimel Extra, Nutricia
GmbH, Germany), which was calculated from the average pre-
investigational amount of consumed carbohydrates during the
last 4 weeks prior to the start of the study. The standardized meal
and the reduced bolus insulin dose were administered exactly 4 h
before the cycle ergometer exercise tests. The bolus insulin dose
was reduced by 40% of the regular dose for the CPX testing. Both
groups were informed to ingest carbohydrate enriched meals at
least the day prior CPX testing to ensure adequate tissue glycogen
stores.
Statistical Analyses
All data were tested with Shapiro-Wilk normality test and were
found to be normally distributed. Descriptive statistics included
mean and standard deviation for participant’s anthropometric
data, performance characteristics, and diabetes specific data.
Anthropometric data and kHR were compared between groups
by paired students’ t-test. Differences in comparison of groups
for thresholds LTP1, VT1, LTP2, VT2, and heart rate turn
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point for relative and absolute power output, heart rate, oxygen
consumption and lactate concentration were analyzed by a two-
way ANOVA (group and threshold), with Bonferroni post-hoc
testing. All statistics were performed with a standard software
package R©Prism Software version 5.0 (GraphPad, USA) and SPSS
22.0 software (SPSS Inc., USA).
RESULTS
Post-hoc power analysis was performed for the primary outcome
percentages of heart rate comparing markers of lowest significant
difference between groups (VT1) and revealed a post hoc power
1-β = 0.99. There were no episodes of hypoglycemia noted
during the CPX testing in the T1D group. T1D individuals
maintained a blood glucose steady state during CPX testing
showing no significant difference between the start (10.58± 3.42
mmol.l−1) and the end concentrations (10.24 ± 3.48 mmol.l−1)
(p= 0.86).
Cardio-respiratory and metabolic markers at LTP1 and VT1
[T1D: p = 0.98 (heart rate), p = 0.99 (oxygen uptake), p = 0.92
(lactate concentration); CON: p = 0.96 (heart rate), p = 0.60
(oxygen uptake), p = 0.96 (lactate concentration)] as well as
LTP2, VT2 and heart rate turn point [T1D: p = 0.93 (heart
rate), p= 0.99 (oxygen uptake), p= 0.58 (lactate concentration);
CON: p = 0.37 (heart rate), p = 0.97 (oxygen uptake), p = 0.76
(lactate concentration)] were not significantly different within
both groups.
No significant differences were found for power output, heart
rate, oxygen uptake and lactate concentration at LTP1, LTP2,
heart rate turn point, and maximum power output between T1D
and CON individuals, except for lactate concentration at LTP1
(Table 1).
Significantly lower values were found for heart rate at
percentages of maximum heart rate at LTP1, VT1, LTP2,
VT2, and heart rate turn point as well as for heart rate at
percentages of heart rate reserve at LTP2, VT2, and heart
rate turn point in T1D individuals (p < 0.05). No significant
differences were found for the oxygen uptake at percentages
of maximum oxygen uptake (p = 0.88), oxygen uptake at
percentages of oxygen uptake reserve (p = 0.71) and heart
rate at percentages of heart rate reserve (only for LTP1 and
VT1, p = 0.11) as well as percentages of maximum power
output %P (p = 0.64) at LTP1, VT1, LTP2, VT2, and heart
rate turn point when comparing T1D and CON individuals
(Figure 1).
kHR was significantly lower in T1D individuals compared
to CON individuals (0.11 ± 0.25 vs. 0.51 ± 0.32, p = 0.02).
Figure 2 shows the time course of the heart rate to performance
curve for both groups indicating the differences especially
important for the upper limit for vigorous intensity exercise.
Usually, maximum heart rate derived calculations of the target
training heart rate overestimate the true limits, as this can
be seen via lactate turn points (Figure 2). The usual upper
limit of 85% of the maximum heart rate was clearly above
the exercise intensity of LTP2 for T1D individuals and clearly
below LTP2 for CON individuals. Eighty-five percent of the
TABLE 1 | Comparison of anthropometric data, performance data and
physiological data during CPX testing.
T1D (n = 7) CON (n = 7) p-value
Age (years) 24.5 ± 5.3 23.4 ± 4.1 0.47
BMI (kg/m2) 23.9 ± 2.5 23.4 ± 1.8 0.70
HbA1c (%) 7.4 ± 0.6 – –
HbA1c (mmol.mol
−1 ) 57 ± 6.3 – –
Diabetes duration (years) 16.9 ± 8.1 – –
PLTP1 (Watt) 83 ± 18 92 ± 22 0.41
PVT1 (Watt) 82 ± 8 103 ± 12 0.17
PLTP2 (Watt) 192 ± 33 197 ± 30 0.74
PVT2 (Watt) 193 ± 14 198 ± 15 0.80
PHRTP (Watt) 198 ± 40 197 ± 30 0.93
Pmax (Watt) 284 ± 43 296 ± 37 0.58
HRLTP1 (b.min
−1) 116 ± 14 127 ± 12 0.13
HRVT1 (b.min
−1) 116 ± 5 128 ± 5 0.14
HRLTP2 (b.min
−1) 159 ± 11 165 ± 10 0.28
HRVT2 (b.min
−1) 159 ± 4 166 ± 5 0.17
HRHRTP (b.min
−1 ) 160 ± 10 165 ± 10 0.38
HRmax (b.min
−1) 192 ± 4 187 ± 11 0.30
VO2LTP1 (ml.kg
−1.min−1 ) 19.88 ± 14 20.53 ± 2.73 0.80
VO2VT1 (ml.kg
−1.min−1 ) 19.89 ± 2.75 19.73 ± 1.11 0.95
VO2LTP2 (ml.kg
−1.min−1 ) 38.20 ± 9.05 38.26 ± 4.21 0.98
VO2VT2 (ml.kg
−1.min−1 ) 38.67 ± 3.50 38.07 ± 2.02 0.88
VO2HRTP (ml.kg
−1.min−1 ) 39.82 ± 10.93 38.61 ± 4.58 0.79
VO2max (ml.kg
−1.min−1 ) 52.49 ± 6.56 52.39 ± 8.57 0.98
LALTP1 (mmol.l
−1 ) 0.91 ± 0.24 1.50 ± 0.58 0.03*
LAVT1 (mmol.l
−1 ) 0.90 ± 0.11 1.48 ± 0.24 0.05
LALTP2 (mmol.l
−1 ) 3.68 ± 0.53 4.10 ± 0.50 0.16
LAVT2 (mmol.l
−1 ) 3.75 ± 0.23 4.18 ± 0.21 0.20
LAHRTP (mmol.l
−1 ) 3.98 ± 0.49 3.88 ± 1.12 0.83
LAmax (mmol.l
−1 ) 12.37 ± 1.25 13.10 ± 0.79 0.21
T1D: individuals with type 1 diabetes, CON: healthy individuals, LTP1 , first lactate turn
point; LTP2, second lactate turn point; HRTP, heart rate turn point; max, maximum output;
P, power output; HR, heart rate; VO2, oxygen uptake; LA, lactate concentration; Values
are given as mean ± SD. * represents significant difference.
maximumheart rate resulted in significant differences comparing
T1D vs. CON for oxygen uptake at percentages of maximum
oxygen uptake [mean difference (MD) 11.57, confidence interval
(CI) 0.15 to 22.99 %, p = 0.04], oxygen uptake at percentages
of oxygen uptake reserve (12.86, 1.43 to 24.28, p = 0.02),
and power output at percentages of maximum power output
(12.57, 1.15 to 23.99 %, p = 0.02), but not for heart rate
at percentages of heart rate reserve (3.71, −7.70 to 15.13 %,
p= 0.87).
DISCUSSION
The aim of this study was to investigate the alterations in the
heart rate during CPX testing in T1D individuals compared
to matched CON individuals. kHR was significantly different
between T1D individuals and CON individuals. T1D individuals
showed a lower heart rate of percentages of the maximum
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FIGURE 1 | Comparison of CPX-testing derived markers between both groups for HR at %HRmax (A), HR at %HRR (B), VO2 at %VO2max (C), VO2 at %VO2R (D)
and P at %Pmax (E). %HRmax, percentage of maximum heart rate; %HRR, percentage of heart rate reserve; %VO2max, percentage of maximum oxygen uptake;
%VO2R, percentage of oxygen uptake reserve; %Pmax, percentage of maximum power output; LTP1, first lactate turn point; LTP2, second lactate turn point; HRTP,
heart rate turn point; VT1, first ventilatory threshold; VT2, second ventilatory threshold. Values are given as mean ± SD. Stars represent significant difference,
*p < 0.05, **p < 0.01. Black bar, individuals with type 1 diabetes; grey bar, healthy individuals.
heart rate at the second turn points (LTP2, VT2, heart rate
turn point) and a significantly lower kHR (Figure 2), which
significantly influenced prescription of the target heart rate.
Applying percentages of maximum heart rate derived markers
overestimated T1D individuals’ target training heart rate which
is important especially for the upper limits for vigorous intensity
exercise. All threshold values within groups were not significantly
different (LTP1 vs. VT1; LTP2 vs. VT2 vs. heart rate turn point)
indicating the objectivity and the validity of these markers which
may be used interchangeably.
Different methods to prescribe exercise intensity for physical
training show different advantages and disadvantages. As shown
by our data, using percentages of maximum values [e.g.,
maximum heart rate or oxygen uptake (6)] is not sufficient to
prescribe exercise intensity individually andmight be impaired in
patients with cardio-respiratory diseases. Submaximal threshold
concepts (e.g., lactate-, ventilatory- and heart rate-derived) are a
valid approach due to their theoretical foundation and its internal
consistency. However, it must be stated that especially rater-
depending software programsmight be influenced by subjectivity
that can alter exercise intensity prescription. Although oxygen
uptake at percentages of maximum oxygen uptake, oxygen
uptake at percentages of oxygen uptake reserve and heart rate
at percentages of heart rate reserve (only for LTP1 and VT1)
were not significantly different at all submaximal markers, heart
rate at percentages of maximum heart rate at LTP1, VT1 and
LTP2, VT2 and heart rate turn point as well as percentages
of heart rate reserve at LTP2, VT2 and heart rate turn point
were significantly lower in T1D individuals compared to CON
individuals. It was previously shown that these differences were
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FIGURE 2 | Comparison of the relative heart rate performance curves and
lactate curves between both groups. The same relative intensity of 85%
HRmax, which is a usual upper limit for moderate intensity, resulted in different
workloads related to the LTP2. %HRmax, percentage of maximum heart rate;
LA, lactate concentration; %Pmax, percentage of maximum power output;
LTP1, first lactate turn point; LTP2, second lactate turn point; HRTP, heart rate
turn point. Values are given as mean ± SD.
also found in young healthy and trained subjects (26) with about
15% of non-regular heart rate curves. However, in our study
62.5% of T1D individuals showed an atypical heart rate response.
In several studies, it was shown that kHR was associated
with left ventricular ejection fraction (12, 16, 27) and β1-
adrenoceptor sensitivity (28). In particular chronically elevated
HbA1c levels and concomitantly elevated catecholamine levels
(29) or inflammation (30) may impair β1-adrenoreceptor
sensitivity. This might change the degree and direction of
the deflection of the heart rate to performance curve as
shown earlier by Wonisch et al. (10). Apart from the
effects of chronic hyperglycemia, hypoglycemic episodes might
further promote impaired cardiovascular function (31). T1D
individuals experience on average two episodes of symptomatic
hypoglycemia per week and at least one severe episode per
year (32). Additionally, the incidence of severe hypoglycemia
increases drastically with length of diabetes. Both hyperglycemia
and recurrent hypoglycemia might be perpetrators for an
impaired cardiac response during CPX testing in individuals
with T1D. Overall, our data show a systematic overestimation of
target heart rate in T1D individuals when applying percentages
of maximum heart rate compared to objective individual markers
of submaximal performance such as LTP1, VT1, LTP2, VT2, and
heart rate turn point.
With respect to the findings in our study we consequently
recommend using percentages of submaximal markers [e.g., the
first and the second turn points for lactate (LTP1 and LTP2)
or ventilatory variables (VT1, VT2)] for the exercise intensity
prescription in T1D which were shown to be representative for
constant and intermittent type exercise of various intensities
(6, 20, 25). As shown in Figure 2, individuals with T1D might be
exercising at a too high exercise intensity if exercise is prescribed
by percentages of maximum heart rate. From a clinical point
of view exercise intensity should be prescribed exactly to avoid
both, unexpected hypoglycemia and to induce training effects.
Since insulin needs to be reduced with light to moderate exercise
intensity to avoid peri-exercise hypoglycemia, glucose levels
remain relatively stable during exercise with vigorous intensity
(33) and rise immediately after intense exercise is performed (34).
If exercise intensity and the insulin dose reduction do not match
accordingly, the risk of glycemic impairments rises (35) which
could lead to severe health complications, including death (36).
On the other hand, if the exercise intensity is close or below the
LTP1, sub-optimal training effects on cardio-respiratory fitness
may be expected, which reduces the possibility of attaining the
accompanied health benefits.
To the best of our knowledge, this is the first study
investigating the differences in cardio-pulmonary responses of
the heart rate, heart rate reserve, oxygen uptake, and oxygen
uptake reserve as well as maximum power output in relation to
objective submaximal markers LTP1, VT1, LTP2, VT2, and heart
rate turn point during CPX testing in T1D individuals and age,
gender- andmaximumpower output- matched CON individuals.
This study is limited by the small number of participants and that
only males were included, which makes a direct transfer of the
results to the general population of individuals with T1D difficult.
Additionally, CON individuals were not provided with the same
meal prior to the CPX testing as the T1D individuals. Further
large-scale studies are needed investigating the heart rate to
performance curve, which is obviously altered in this population.
However, post-hoc power analysis confirmed the relevance of this
study (power 1-β= 0.99).
In conclusion, our findings demonstrate that there are
clear differences in heart rate responses during CPX testing
in individuals with T1D compared to CON individuals. We
postulate that T1D individuals displayed an altered kHR and
lowered percentages of maximum heart rate / percentages of
heart rate reserve at submaximal markers. We recommend
additional studies to analyze e.g., HbA1c levels in relation to the
heart rate to performance curve in a larger group of individuals
with T1D.
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